Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm ...

We expect these to return in EA FC 25 once again. The devs also like to throw new special card campaigns into the mix as well, but these won’t be announced until a day or two before they are due ...

Botensilimab is a human Fc enhanced CTLA-4 blocking antibody designed ... fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting ...

据中国国家药监局 (NMPA)官方批件信息，2025 年 3 月，三款罕见病药物于国内首次获批上市，或迎来新适应症，为对应病症的患者群体带来全新的治疗选择。下面，让我们一起了解这三款新药的具体情况。

Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for ...

At close: April 9 at 4:00:03 PM EDT ...

Botensilimab is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend ...

这种全人群覆盖的优势，本质上改变了传统按治疗方式划分适应症的模式。从技术原理看，舒格利单抗采用全人源化IgG4单抗设计，相较于同类药物具有更优的Fc段改造，可能带来更持久的肿瘤微环境调控能力。 中国创新药企的国际化路径正在发生质变。基石药业 ...